Mirus and Reinnervate to Commercialize 3-D Transfection Kits
Kits combine Reinnervate’s Alevtex scaffold with Mirus’ TransIT transfection reagents.!--h2>
Reinnervate and Mirus Bio inked an agreement to commercialize a range of products for transfecting cells cultured in 3-D. Mirus will produce and sell kits that combine its own TransIT®-3D tranfection reagent with Reinnervate’s alvetex® plates. The kits will be supplied with detailed protocols for achieving transfection of selected cell lines growing in 3-D.
Alvetex is a polystyrene material developed by 3-D cell culture specialist Reinnervate, which the firm claims provides a scaffold that allows cells to grow and form 3-D structures that mimic normal growth and formation of tissues in the body. The platform has been tested and validated with a range of cell types, and is available in formats including a 12-well culture plate, 6-well and 12-well inserts, and a deep petri dish.
U.K.-based transfection specialist Mirus Bio’s TransIT transfection reagents are designed to enable the efficient delivery of all types of nucleic acids and oligonucleotides to eukaryotic cells. The firm offers a range of transfection reagents and transfection kits, including cell line-specific products, reporter assays, and reagents/kits for the delivery of DNA, viral RNA, mRNA, siRNA, and oligonucleotides. The firm has in addition launched its TransIT-Pro Transfection kit for the production of proteins in CHO and 293 cells.